Sphingosine Kinase 1: A Potential Therapeutic Target in Pulmonary Arterial Hypertension?

Trends Mol Med

Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral St, Glasgow, G4 0RE Scotland, UK.

Published: September 2017

Sphingosine kinase 1 (SphK1) knockout mice are protected against pulmonary hypertension and expression levels of the enzyme are increased in the lungs of pulmonary arterial hypertensive (PAH) patients. Moreover, sphingosine 1-phosphate can promote vascular remodeling/vasoconstriction in rodent and human pulmonary arterial smooth muscle cell models. Therefore, SphK1 might be a novel target for treatment of PAH. However, in our opinion, more refined strategies to target SphK1 are needed because this enzyme is protective against endothelial dysfunction and can become resistant to SphK1 inhibitors in vascular smooth muscle, thereby potentially limiting their effectiveness in PAH. In addition, SphK1 is involved in maladaptive hypertrophy and we propose that heart failure might be an additional direct target for therapeutic intervention with SphK1 inhibitors.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molmed.2017.07.001DOI Listing

Publication Analysis

Top Keywords

pulmonary arterial
12
sphingosine kinase
8
smooth muscle
8
sphk1 inhibitors
8
sphk1
6
kinase potential
4
potential therapeutic
4
target
4
therapeutic target
4
pulmonary
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!